Cargando…
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
The historical lack of preclinical models reflecting the genetic heterogeneity of multiple myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this limitation, we screened mice engineered to carry eight MM lesions (NF-κB, KRAS, MYC, TP53, BCL2, cyclin D1, MMSET/NSD2 and c-MAF)...
Ejemplares similares
-
Preneoplastic somatic mutations including MYD88(L265P) in lymphoplasmacytic lymphoma
por: Rodriguez, Sara, et al.
Publicado: (2022) -
Mutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia (AML) with Normal Cytogenetics
por: Fernandez-Mercado, Marta, et al.
Publicado: (2012) -
Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor
por: Lozano, Teresa, et al.
Publicado: (2017) -
Helper cell-independent antitumor activity of potent CD8(+) T cell epitope peptide vaccines is dependent upon CD40L
por: Llopiz, Diana, et al.
Publicado: (2013) -
IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination
por: Llopiz, Diana, et al.
Publicado: (2016)